Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Cutting Edge: HDAC3 Protects Double-Positive Thymocytes from P2X7 Receptor–Induced Cell Death
Philips, Rachael L. , McCue, Shaylene , Rajcula, Matthew, Shapiro, Virginia Smith , Shapiro, Virginia S

Mayo Clinic

The Journal of Immunology | January 9, 2019 | Volume: 202 | Issue: 4 | Pages: 1033-1038

10.4049/jimmunol.1801438 | PMID 30626694 Get It

Abstract Intricate life-versus-death decisions are programmed during T cell development, and the regulatory mechanisms that coordinate their activation and repression are still under investigation. In this study, HDAC3-deficient double-positive (DP) thymocytes exhibit a severe decrease in numbers. The thymic cortex is rich in ATP, which is released by macrophages that clear apoptotic DP thymocytes that fail to undergo positive selection. We demonstrate that HDAC3 is required to repress expression of the purinergic receptor P2X7 to prevent DP cell death. HDAC3-deficient DP thymocytes upregulate the P2X7 receptor, increasing sensitivity to ATP-induced cell death. P2rx7/HDAC3-double knockout mice show a partial rescue in DP cell number. HDAC3 directly binds to the P2rx7 enhancer, which is hyperacetylated in the absence of HDAC3. In addition, RORγt binds to the P2rx7 enhancer and promotes P2X7 receptor expression in the absence of HDAC3. Therefore, HDAC3 is a critical regulator of DP thymocyte survival and is required to suppress P2X7 receptor expression.
The Evolving Clinical Landscape for Dendritic Cell Vaccines and Cancer Immunotherapy
Cannon, Martin J. , Block, Matthew S. , Morehead, Lauren C. , Knutson, Keith L. , Knutson, Keith L.

Mayo Clinic

Immunotherapy | January 9, 2019 | Volume: 11 | Issue: 2 | Pages: 75-79

10.2217/imt-2018-0129 | PMID 30730268 Get It

Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle‐invasive bladder cancer treated with cisplatin‐based neoadjuvant chemotherapy and radical cystectomy: a single‐centre experienc
Soligo, Matteo, Frank, Igor, Boorjian, Stephen A. , Thompson, R. Houston, Tollefson, Matthew K. , Cheville, John C. , Karnes, R. Jeffrey , Thompson, Robert H, Tollefson, Matthew, Quevedo, Fernando J, Karnes, Jeffrey , Boeri, Luca , Quevedo, Fernando

Mayo Clinic

BJU International | January 9, 2019 | Volume: 123 | Issue: 6 | Pages: 1011-1019

10.1111/bju.14612 | PMID 30623554 Get It

Objective To investigate the association between smoking status and pathological response to cisplatin‐based neoadjuvant chemotherapy ( NAC ) and survival outcomes in patients with muscle‐invasive bladder cancer ( MIBC ) treated with radical cystectomy ( RC ). Patients and Methods We reviewed 201 patients treated with NAC and RC for cT 2– cT 4N0M0 BC between 01/1999 and 01/2015. Smoking status was categorised as: ‘never', ‘former', and ‘current' smoker. Pathological response to NAC was defined as: complete (ypT0N0), partial (ypTis/Ta/T1, N0), and no response (ypT2–4 or ypN+). Clinicopathological characteristics were analysed according to smoking status. Logistic regression analyses tested the association between smoking status and pathological response to NAC . Cox regression analyses tested risk factors associated with recurrence, overall ( OM ) and cancer‐specific mortality ( CSM ). Results Overall, there were 58 (28.9%) never smokers, 87 (43.3%) former smokers, and 56 (27.9%) current smokers. No response to NAC was more frequently noted in current smokers (73.2%; P = 0.007). Former smoker ( odds ratio [OR] 2.28; P = 0.024) and current smoker statuses ( OR 4.52; P < 0.001) were significantly associated with no response to NAC , after adjusting for age, gender, Charlson Comorbidity Index, and clinical stage. Similarly, current smoking status ( hazard ratio [HR] 2.14; P = 0.03) and extravesical pathological tumour stage ( HR 3.31; P < 0.001) were independently associated with an increased risk of recurrence after RC . Conclusion Cigarette smoking was significantly associated with adverse pathological response to cisplatin‐based NAC in patients with MIBC treated with RC . Current smokers were at significantly higher risk of disease recurrence as compared to former and never smokers.
Not All Cellular Rejections Are the Same: Differences in Early and Late Hepatic Allograft Rejection
Morgan, Paige , Nehra, Avinash , Hathcock, Matthew , Kremers, Walter K. , Wiesner, Russell H., Taner, Timuçin , Morgan, Paige E, Nehra, Avinash K, Hathcock, Matthew A, Taner, Timucin , Kremers, Walter K , Jadlowiec, Caroline C. , Morgan, Paige E., Heimbach, Julie K.

Mayo Clinic

Liver Transplantation | January 8, 2019 | Volume: 25 | Issue: 3 | Pages: 425-435

10.1002/lt.25411 | PMID 30615251 Get It

T cell–mediated rejection (TCMR) is common after liver transplantation (LT), and it is often thought to have a minimum impact on outcomes. Because alloimmune response changes over time, we investigated the role of the timing of TCMR on patient and allograft survival and examined the risk factors for early and late TCMR. We reviewed protocol liver biopsies for 787 consecutive LT recipients with an 8.6‐year follow‐up. The incidence of early TCMR (≤6 weeks after LT) was 33.5% with nonalcoholic steatohepatitis patients having the lowest incidence. Younger recipient age (P < 0.01), number of human leukocyte antigen mismatches (P < 0.01), and use of deceased donor allografts (P = 0.01) were associated with increased risk of early TCMR, which had no impact on allograft (hazard ratio [HR], 1.02; 95% CI, 0.79‐1.32; P = 0.89) or overall survival (HR, 1.03; 95% CI, 0.78‐1.34; P = 0.86). Late TCMR (>6 weeks after LT) was less common (17.7%) and was associated with different risk factors. The majority of late TCMR (56.2%) episodes had no antecedent early TCMR, although moderate‐to‐severe early TCMR (HR, 2.85; 95% CI, 1.55‐5.23; P < 0.01) and steroid resistance (HR, 3.62; 95% CI, 1.87‐6.99; P < 0.01) were associated with late TCMR. Late TCMR increased risk of mortality (HR, 1.89; 95% CI, 1.35‐2.65; P = 0.001) and graft loss (HR, 1.71; 95% CI, 1.23‐2.37; P = 0.001). Thus, these data suggest that the timing and histologic grade of TCMR determine its impact on patient and allograft survival. Early mild TCMR episodes after LT do not adversely impact patient or allograft survival provided that they are adequately treated. The occurrence of late TCMR carries deleterious effects with increased longterm risk of graft loss and decreased survival. Patients with moderate‐to‐severe early TCMR are at an increased risk for late TCMR and warrant closer clinical follow‐up.
Probing the Virtual Proteome to Identify Novel Disease Biomarkers
Smith, J. G. , Melander, Olle , Ngo, Debby , Shaffer, Christian M., Ferguson, Jane F. , Herzig, Matthew , McCarty, Catherine A. , Jarvik, Gail P. , Gordon, Allan , Palmer, Melody R. , Crosslin, David R. , Larson, Eric B. , Pacheco, Jennifer A. , Peissig, Peggy , Brilliant, Murray H. , Kitchner, Terrie, Linneman, James G., Namjou, Bahram , Ritchie, Marylyn D. , Borthwick, Kenneth M., Kiryluk, Krzysztof , Mentch, Frank , Sleiman, Patrick , Karlson, Elizabeth W. , Zhu, Yineng, Denny, Joshua C. , Roden, Dan M. , Gerszten, Robert E. , Wang, Thomas J. , Denny, Joshua C , Jarvik, Gail P , Gordon, Adam S , Pacheco, Jennifer A , Kiryluk, Krzysztof , Ferguson, Jane F , Mosley, Jonathan D , Benson, Mark D. , Chute, Christopher G. , Carrell, David , Kullo, Iftikhar J. , Williams, Marc S , Verma, Shefali S. , Vasan, Ramachandran S. , Yang, Qiong , Roden, Dan M. , Smith, J Gustav

Mayo Clinic

Circulation | January 7, 2019 | Volume: 138 | Issue: 22 | Pages: 2469-2481

10.1161/circulationaha.118.036063 | PMID 30571344 Get It

Background: Proteomic approaches allow measurement of thousands of proteins in a single specimen, which can accelerate biomarker discovery. However, applying these technologies to massive biobanks is not currently feasible because of the practical barriers and costs of implementing such assays at scale. To overcome these challenges, we used a “virtual proteomic” approach, linking genetically predicted protein levels to clinical diagnoses in >40 000 individuals. Methods: We used genome-wide association data from the Framingham Heart Study (n=759) to construct genetic predictors for 1129 plasma protein levels. We validated the genetic predictors for 268 proteins and used them to compute predicted protein levels in 41 288 genotyped individuals in the Electronic Medical Records and Genomics (eMERGE) cohort. We tested associations for each predicted protein with 1128 clinical phenotypes. Lead associations were validated with directly measured protein levels and either low-density lipoprotein cholesterol or subclinical atherosclerosis in the MDCS (Malmö Diet and Cancer Study; n=651). Results: In the virtual proteomic analysis in eMERGE, 55 proteins were associated with 89 distinct diagnoses at a false discovery rate q<0.1. Among these, 13 associations involved lipid (n=7) or atherosclerosis (n=6) phenotypes. We tested each association for validation in MDCS using directly measured protein levels. At Bonferroni-adjusted significance thresholds, levels of apolipoprotein E isoforms were associated with hyperlipidemia, and circulating C-type lectin domain family 1 member B and platelet-derived growth factor receptor-β predicted subclinical atherosclerosis. Odds ratios for carotid atherosclerosis were 1.31 (95% CI, 1.08–1.58; P =0.006) per 1-SD increment in C-type lectin domain family 1 member B and 0.79 (0.66–0.94; P =0.008) per 1-SD increment in platelet-derived growth factor receptor-β. Conclusions: We demonstrate a biomarker discovery paradigm to identify candidate biomarkers of cardiovascular and other diseases.
Patient-derived xenografts from breast cancer patients before and after neoadjuvant chemotherapy: A prospective study.
Yu, Jia , Gao, Bowen , Moyer, Ann M. , Visscher, Daniel W., Conners, Amy Lynn , Dockter, Travis , Jones, Katie N., McLaughlin, Sarah A. , Copland, John A. , Moreno‐Aspitia, Alvaro , Northfelt, Donald W. , Gray, Richard J. , Weinshilboum, Richard M. , Wang, Liewei , Boughey, Judy C. , Yin, Ping , Sinnwell, Jason P. , Kalari, Krishna R. , Suman, Vera J. , Weinshilboum, Richard M. , Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 11130-11130

10.1200/jco.2014.32.15_suppl.11130 Get It

An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome, mate-pair sequencing data.
Asmann, Yan W. , Necela, Brian M. , Chen, Xianfeng , Kocher, Jean‐Pierre , Feldman, Andew L., Novak, Anne J. , Perez, Edith A. , Thompson, E. Aubrey , Wang, Chen , Maurer, Matthew J. , Habermann, Thomas M. , Slager, Susan L. , Doǧan, Ahmet , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e22171-e22171

10.1200/jco.2014.32.15_suppl.e22171 Get It

Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC).
Rizvi, Naiyer A. , Patnaik, Amita , Balmanoukian, Ani Sarkis, Blumenschein, George R. , Gubens, Matthew A. , Papadopoulos, Kyriakos P. , Lubiniecki, Gregory M., Zhang, Jin , Niewood, Michelle, Emancipator, Kenneth , Dolled‐Filhart, Marisa, Hanson, Mary E. , Hui, Rina , Garon, Edward B. , Gandhi, Leena , Leighl, Natasha B , Goldman, Jonathan W. , Eder, Joseph P. , Johnson, Elizabeth Anne

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8007-8007

10.1200/jco.2014.32.15_suppl.8007 Get It